Literature DB >> 24107846

Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification.

Jane L Finch1, Duk H Lee, Helen Liapis, Cindy Ritter, Sarah Zhang, Edu Suarez, Leon Ferder, Eduardo Slatopolsky.   

Abstract

The role of hyperphosphatemia in the pathogenesis of secondary hyperparathyroidism, cardiovascular disease, and progression of renal failure is widely known. Here we studied effects of dietary phosphate restriction on mortality and vascular calcification in uremic rats. Control and uremic rats were fed a high-phosphate diet and at 3 months a portion of rats of each group were killed. Serum phosphate and the calcium phosphate product increased in uremic rats, as did aortic calcium. Of the rats, 56% had positive aortic staining for calcium (von Kossa), RUNX2, and osteopontin. The remaining uremic rats were continued on diets containing high phosphate without and with sevelamer, or low phosphate, and after 3 more months they were killed. Serum phosphate was highest in uremic rats on high phosphate. Serum PTH and FGF-23 were markedly lower in rats on low phosphate. Mortality on high phosphate was 71.4%, with sevelamer reducing this to 37.5% and phosphate restriction to 5.9%. Positive aortic staining for von Kossa, RUNX2, and osteopontin was increased, but phosphate restriction inhibited this. Kidneys from low-phosphate and sevelamer-treated uremic rats had less interstitial fibrosis, glomerulosclerosis, and inflammation than those of uremic rats on high phosphate. Importantly, kidneys from rats on low phosphate showed improvement over kidneys from high-phosphate rats at 3 months. Left ventricles from rats on low phosphate had less perivascular fibrosis and smaller cardiomyocyte size compared to rats on high phosphate. Thus, intensive phosphate restriction significantly reduces mortality in uremic rats with severe vascular calcification.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107846      PMCID: PMC6589836          DOI: 10.1038/ki.2013.213

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

Review 1.  Dietary Phosphorus Intake and the Kidney.

Authors:  Alex R Chang; Cheryl Anderson
Journal:  Annu Rev Nutr       Date:  2017-06-14       Impact factor: 11.848

Review 2.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

Review 3.  Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho.

Authors:  Shunsuke Yamada; Cecilia M Giachelli
Journal:  Bone       Date:  2016-11-12       Impact factor: 4.398

Review 4.  Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity.

Authors:  Ronald B Brown; Mohammed S Razzaque
Journal:  Bonekey Rep       Date:  2015-06-03

5.  Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial.

Authors:  Alex R Chang; Edgar R Miller; Cheryl A Anderson; Stephen P Juraschek; Melissa Moser; Karen White; Bobbie Henry; Caitlin Krekel; Susan Oh; Jeanne Charleston; Lawrence J Appel
Journal:  Am J Kidney Dis       Date:  2016-11-16       Impact factor: 8.860

Review 6.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 7.  Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond?

Authors:  Grace J Lee; Joanne Marks
Journal:  Pediatr Nephrol       Date:  2014-02-05       Impact factor: 3.714

8.  Phosphate restriction using a processed clay mineral reduces vascular pathologies and microalbuminuria in rats with chronic renal failure.

Authors:  Jacqueline Hofrichter; Kai Sempert; Claus Kerkhoff; Anne Breitrück; Reinhold Wasserkort; Steffen Mitzner
Journal:  BMC Nephrol       Date:  2022-04-28       Impact factor: 2.585

9.  Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease.

Authors:  Mark R Hanudel; Brian Czaya; Shirley Wong; Grace Jung; Kristine Chua; Bo Qiao; Victoria Gabayan; Tomas Ganz
Journal:  Sci Rep       Date:  2022-04-23       Impact factor: 4.996

Review 10.  Medial vascular calcification revisited: review and perspectives.

Authors:  Peter Lanzer; Manfred Boehm; Victor Sorribas; Marc Thiriet; Jan Janzen; Thomas Zeller; Cynthia St Hilaire; Catherine Shanahan
Journal:  Eur Heart J       Date:  2014-04-16       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.